Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000040466 | SCV000064157 | likely benign | not specified | 2012-05-01 | criteria provided, single submitter | clinical testing | Val18618Val in exon 255 of TTN: This variant is not expected to have clinical si gnificance because it does not alter an amino acid residue and is not located wi thin the splice consensus sequence. Val18618Val in exon 255 of TTN (allele freq uency = n/a) |
Labcorp Genetics |
RCV002054796 | SCV002481652 | likely benign | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2024-10-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002453329 | SCV002615982 | uncertain significance | Cardiovascular phenotype | 2021-02-25 | criteria provided, single submitter | clinical testing | The c.36363G>A variant (also known as p.V12121V), located in coding exon 133 of the TTN gene, results from a G to A substitution at nucleotide position 36363. This nucleotide substitution does not change the valine at codon 12121. This nucleotide position is not well conserved in available vertebrate species. In silico splice site analysis for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |